title: Perinatal aspects of iron metabolism.
abstract: Iron sufficiency is critical for rapidly developing fetal and neonatal organ systems. The majority of iron in the third trimester fetus and the neonate is found in the red cell mass (as hemoglobin), with lesser amounts in the tissues as storage iron (e.g. ferritin) or functional iron (e.g. myoglobin, cytochromes). Iron is prioritized to hemoglobin synthesis in red cells when iron supply does not meet iron demand. Thus, non-heme tissues such as the skeletal muscle, heart and brain will become iron deficient before signs of iron-deficiency anemia. Gestational conditions that result in lower newborn iron stores include severe maternal iron deficiency, maternal hypertension with intrauterine growth retardation and maternal diabetes mellitus. Stable, very low birthweight premature infants are also at risk for early postnatal iron deficiency because they accrete less iron during gestation, grow more rapidly postnatally, are typically undertreated with enteral iron and receive fewer red cell transfusions. Conversely, iron overload remains a significant concern in multiply transfused sick preterm infants because they have low levels of iron-binding proteins and immature antioxidant systems.
  
  
  CONCLUSIONS
  The highly variable iron status of preterm infants combined with their risk for iron deficiency and toxicity warrants careful monitoring and support in the newborn and postdischarge periods.
authors.affiliation: Division of Neonatology, Department of Pediatrics and Center for Neurobehavioral Development, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
authors.forename: R
authors.initials: R
authors.lastname: Rao
authors.forename: M K
authors.initials: MK
authors.lastname: Georgieff
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D003131:Combined Modality Therapy; D017707:Erythrocyte Transfusion / Q000379:methods; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005317:Fetal Growth Retardation / Q000150:complications / Q000175:diagnosis; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D058085:Iron Compounds / Q000009:adverse effects / Q000627:therapeutic use; D019189:Iron Metabolism Disorders / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D019190:Iron Overload / Q000517:prevention & control*; D008431:Maternal-Fetal Exchange; D010500:Perinatology; D011247:Pregnancy; D011994:Recombinant Proteins; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D058085:Iron Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin